ACOR

AcronymDefinition
ACORAssociation of Cancer Online Resources
ACORAmerican Center of Oriental Research
ACORAmerican Conference on Oriental Rugs (est. 1992)
ACORAdvanced Certificate in Operational Risk
ACORAfrican American Coalition of Reading (Reading, PA)
ACORAssistant Contracting Officer Representative
ACORAustralian Council of Recycling (Australia)
ACORAdvisory Committee on Research (Canadian Cancer Society Research Institute)
ACORAfrican Commercial Representation (Abidjan, Ivory Coast)
ACORAir Care on Road (Canada)
ACORAgreed Cost of Repair (insurance)
ACORActual Cost of Repair
ACORAdministrative Contracting Officers Representative
References in periodicals archive ?
Talal Abu-Ghazaleh, Federico Vidic, head of the Cultural office of the Italian Embassy, Barbara Porter, the ACOR director and Ali al-Khayat, assistant Director General of the Department of Archaeology.
The client loved it, and it is producing solid results," Acor said.
"Acor provides excellent training and a great product, and those franchisees that are promoting it are realizing success, as Medicare pays for a large portion of the costs of these products.
Shares of Acorda Therapeutics, Inc.(NASDAQ: ACOR) were down 39% to $3.71 after the company reported Q2 results.
Barbara Porter, Director of the American Center of Oriental Research (ACOR), and ICOMOS-Jordan President HRH Princess Dana Firas inked the agreement.
- The US Food and Drug Administration has accepted US-based biopharmaceutical company Acorda Therapeutics, Inc.'s (NASDAQ: ACOR) new drug application (NDA) for Inbrija, an investigational inhaled levodopa treatment for symptoms of OFF periods in people with Parkinson's disease taking a carbidopa/levodopa regimen, the company said.
Lennon's pal, Pete Shotton: "What are you working on at the moment, Yoko?" Ono: "I'm thinking about acor ns."
Tickers featured: ACOR, ALXN, AMLN, ARYX, AVGN, BIIB, BMRN, CRME, DNDN, GENZ, GILD, MDVN, MITI, MYGN, SQNM, VRTX, XNPT.
Shares of Acorda Therapeutics, Inc.(NASDAQ: ACOR) were down 45% to $3.2950 after the company reported Q2 results.
Acorda Therapeutics (ACOR) downgraded to Sell from Neutral at Goldman Sachs with analyst Salveen Richter saying the commercial outlook for Inbrija appears limited.
(NASDAQ: ACOR) has resubmitted its New Drug Application for Inbrija to the US Food and Drug Administration, the company said.
(NASDAQ: ACOR) has closed its purchase of the shares, American Depositary Shares, stock options, share units and warrants in Finnish drug development company Biotie Therapies Corp (NASDAQ: BITI) that were tendered during its offer period, the company said on Monday.